Multiple Myeloma Research Consortium (MMRC) Presents Data at the 50th Annual American Society of Clinical Oncology Meeting (ASCO), May 30-June 3, Chicago

Presentation Includes SAR650984 Showing Encouraging Early Results for Heavily Pretreated Multiple Myeloma

Norwalk, CT — May 29, 2014

The Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC) today announced the presentation of a study conducted through its clinical sites in collaboration with industry partner, pharmaceutical company Sanofi, at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 30 – June 3, 2014 in Chicago.

Initial results from a Phase 1 clinical trial show promise for SAR650984 as a therapeutic option for heavily pretreated multiple myeloma patients. SAR650984 is one of several potential new anti-myeloma agents belonging to the same broad class of drugs as elotuzumab, daratumumab and IPH2101, called monoclonal antibodies. Mono¬clon¬al antibodies work by identifying proteins on the surface of myeloma cells and signal¬ing for the im¬mune system to destroy the cancer cells with minimal side effects.

“The MMRC data presented here represents some of the most promising therapeutic options studied to treat myeloma patients with minimal toxicity and no severe or life-threatening blood-related side effects,” said Walter M. Capone, President of the MMRF and the MMRC. “We are grateful for the commitment of our partners who contributed to this trial and are working hard to help develop promising new drugs to accelerate the treatment and cure of myeloma and other cancers.”

The abstract presentation within the MMRC will take place:

Monday, June 2— Lymphoma and Plasma Cell Disorders Symposium: A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

  • Dr. Thomas Martin of UCSF Medical Center
  • Oral Abstract #8512
  • 8:00 AM to 11:00 a.m., E354a

To see the full MMRF coverage from ASCO with ongoing updates, please visit: www.themmrf.org/asco.

About Multiple Myeloma
Multiple myeloma is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 24,050 adults (13,500 men and 10,550 women) in the United States will be diagnosed with multiple myeloma in 2014 and an estimated 11,090 people are predicted to die from the disease. The five-year survival rate for multiple myeloma is approximately 43%, versus 28% in 1998.

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised $250 million since its inception and directs nearly 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.

Dwain Schenck